Matthew J. Thomas

发表

Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice.

N. Morrell, K. Sheppard, L. Ciuclan, 2013, The American journal of pathology.

Targeting the serotonin pathway for the treatment of pulmonary arterial hypertension.

N. Press, L. Ciuclan, M. Hussey, 2013, Pharmacology & therapeutics.

Activity of the Estrogen Metabolising Enzyme Cytochrome P 450 1 B 1 Influences the Development of Pulmonary Arterial Hypertension

J. McClure, I. Morecroft, A. K. Johansen, 2012 .

Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?

Matthew J. Thomas, C. Owen, 2008, Current opinion in pharmacology.

Phosphoinositide 3-kinase (PI3K) family of signalling enzymes and their role in asthma

C. Walker, M. Edwards, Matthew J. Thomas, 2006 .

Genetic ablation of PI3Kγ results in defective IL‐17RA signalling in T lymphocytes and increased IL‐17 levels

P. Finan, J. Westwick, S. Ward, 2012, European journal of immunology.

Activity of the Estrogen-Metabolizing Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary Arterial Hypertension

J. McClure, I. Morecroft, A. K. Johansen, 2012, Circulation.

Pharmacological targets for pulmonary vascular disease: vasodilation versus anti-remodelling.

Matthew J. Thomas, 2010, Advances in experimental medicine and biology.

Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline.

Cerys Docx, C. Leblanc, N. Morrell, 2009, The American journal of pathology.

Regulation and Function of miR-214 in Pulmonary Arterial Hypertension

N. Morrell, L. Denby, M. Maclean, 2016, Pulmonary circulation.

Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

D. Rowlands, M. Maclean, M. Nilsen, 2014, American journal of respiratory and critical care medicine.

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.

D. Budd, S. Watson, S. Charlton, 2017, ACS medicinal chemistry letters.

CD8 T Cell-Dendritic Cell (DC) Interaction in the Regulation of IgE

D. Kemeny, Matthew J. Thomas, 2002 .

Essential role of phosphoinositide 3‐kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation

P. Finan, J. Westwick, E. Hirsch, 2009, Immunology.

Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy.

E. Hirsch, M. Wymann, R. Marone, 2013, The Journal of allergy and clinical immunology.

Sequestration of CD4 Agonist FTY720 Differentially Affects the The Sphingosine 1-Phosphate Receptor

V. Brinkmann, G. Jarai, C. Walker, 2005 .

An Essential Role for IL-18 in CD8 T Cell-Mediated Suppression of IgE Responses1

D. Kemeny, M. Salagianni, A. Noble, 2007, The Journal of Immunology.

CD8 T Cells Inhibit IgE Via Dendritic Cell IL-12 Induction That Promotes Th1 T Cell Counter-Regulation1

P. Askenase, D. Kemeny, A. Noble, 2002, The Journal of Immunology.

Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.

M. Perry, B. Valastro, Matthew J. Thomas, 2019, Journal of medicinal chemistry.

Essential role for the p110δ phosphoinositide 3-kinase in the allergic response

P. Finan, K. Okkenhaug, A. Bilancio, 2004, Nature.

Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.

H. Lindmark, C. Tyrchan, N. Holden, 2018, Journal of medicinal chemistry.

T Cytotoxic 1 and T Cytotoxic 2 CD8 T Cells Both Inhibit IgE Responses

P. MacAry, P. Askenase, D. Kemeny, 2001, International Archives of Allergy and Immunology.

Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases

Matthew Thomas, David Rowlands, Clemens Scheufler, 2017, Front. Pharmacol..

Airway inflammation: chemokine‐induced neutrophilia and the class I phosphoinositide 3‐kinases

P. Finan, J. Westwick, B. Vanhaesebroeck, 2005, European journal of immunology.

MicroRNA-1405 p and SMURF 1 regulate pulmonary arterial hypertension

N. Arnold, D. Rowlands, N. Morrell, 2018 .

MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.

N. Arnold, D. Rowlands, N. Morrell, 2016, The Journal of clinical investigation.

MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.

J. McClure, M. McBride, N. Morrell, 2015, Circulation research.

Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.

N. Waters, E. Vangrevelinghe, G. Hollingworth, 2014, Bioorganic & medicinal chemistry letters.

Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase γ.

Benjamin R Bellenie, G. Hollingworth, M. Bracher, 2021, Journal of medicinal chemistry.

A novel murine model of severe pulmonary arterial hypertension.

J. Westwick, N. Morrell, A. Holmes, 2011, American journal of respiratory and critical care medicine.

Essential role for the p110delta phosphoinositide 3-kinase in the allergic response.

P. Finan, K. Okkenhaug, A. Bilancio, 2004, Nature.

IL-12 Induction That Promotes Th 1 T Cell CD 8 T Cells Inhibit IgE Via Dendritic Cell

P. Askenase, D. Kemeny, A. Noble, 2001 .

Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.

Cerys Docx, J. Westwick, C. Leblanc, 2013, Bioorganic & medicinal chemistry.

A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology

G. Jarai, E. Jarman, Nicholas Duggan, 2014, Physiological reports.

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor for the Treatment of Asthma.

H. Lindmark, U. Börjesson, C. Tyrchan, 2021, Journal of medicinal chemistry.

Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension.

P. Furet, I. Konstantinova, A. Saunders, 2016, Journal of medicinal chemistry.

Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.

I. Clay, J. Westwick, D. Rowlands, 2013, American journal of respiratory and critical care medicine.

Essential role of phosphoinositide 3‐kinase gamma in eosinophil chemotaxis within acute pulmonary inflammation

P. Finan, J. Westwick, E. Hirsch, 2009, Immunology.